The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may cause ARDS)
ILD cases that occurred with combo treatments (methotrexate + adalimumab) (e.g. PMID 24626274) are not included due un uncertain causality
Publications
A Unique Case of Acute Respiratory Distress Syndrome Secondary to Rheumatoid Lung Disease With Administration of Anti-Tumor Necrosis Factor Alpha (TNFα) Agent.
Cureus 2023 Apr;15;e37990 — 2023 Apr
Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.
Annals of the rheumatic diseases 2006 Jun;65;834-5 — 2006 Jun — 834-5